Target overview
Synonyms
TROP2|TACSTD2|Trop-2
Emerging Competitive
TROP2 / TACSTD2
TROP2 / TACSTD2 is flagged as emerging competitive based on 41 active trials across 31 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 45
Active trials: 41
Recruiting trials: 17
Known assets: 2
Sponsor activity
Competitive footprint
Unique sponsors: 31
Top sponsors: ASTRAZENECA | Fudan University | Dana-Farber Cancer Institute
Tumor types: Breast Cancer | Triple Negative Breast Cancer | Advanced Solid Tumors
Patent-density signal summary
Patent layer
Signal count: 1
Recent signals: 1
Top assignees: Gilead Sciences
Signal types: adc_composition
Scores and labels
Deterministic summary
Clinical crowding: 4/5 (High)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 1/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.